New York State Psychiatric Institute
Trial Pipeline
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
NCT05999240
Exercise and Olanzapine-samidorphan
NCT06740890
Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)
NCT05477901
Effects of rTMS on Food Choice in Anorexia Nervosa
NCT05918835
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Clinical Trials of Multivalent Opioid Vaccine Components
NCT04458545
Scaling up e-Connect in Juvenile Probation Settings
NCT05541926
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
NCT05690503
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
NCT05712707
Facilitating Opioid Care Connections
NCT04216719
Facilitating Rapid Naltrexone Initiation
NCT03345173
RCT of a Brief Video Intervention Targeting Peer Inclusion to Reduce Depression-related Stigma in Adolescents
NCT06360107
Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities
NCT04958798
Leveraging Social Networks to Increase COVID-19 Testing Uptake
NCT04873401
Mechanisms of Emotion Regulation Underlying Successful CBT in Depression
NCT04328103
Treating Self Injurious Behavior: A Novel Brain Stimulation Approach
NCT04244786
D-serine Augmentation of Neuroplasticity
NCT03711500
Improving Accessibility and Personalization of CR for Schizophrenia
NCT03576976
Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers
NCT03457077
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
NCT03253926
Neuroimaging in Patients Undergoing TMS for Depression
NCT02974296
Pilot Study of the Impact of Exercise on Hippocampal Function
NCT03036371
Are Bright Lights and Regulated Sleep Effective Treatment for Depression?
NCT03010488
Promoting Mother-Baby Bonding Through a Relaxation Routine During Pregnancy
NCT02943083
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
NCT02803229
Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)
NCT02645929
Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults
NCT02530645
Medication-Assisted Treatment for Youth With Substance Use Disorders
NCT02593474
Personalized Computerized Inhibitory Control Training for OCD
NCT02378896
Biosignatures of Latuda for Bipolar Depression
NCT02239094
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
NCT02473250
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
NCT02267629
Biomarker Assessment of Glutamatergic Target Engagement
NCT02134951
Social Circumstances, Parenting Techniques, and Infant Development
NCT02121496
Personalized and Scalable Cognitive Remediation Approaches
NCT01945333
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
NCT01811940
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
NCT01740414
Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence
NCT01486810
Combination Treatment Study for Memory Impairment and Depression
NCT01658228
Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
NCT01415440
Exercise, Age-Related Memory Decline, And Hippocampal Function
NCT01329653
Improved Strategies for Outpatient Opioid Detoxification
NCT01377610
Glutamatergic Modulation of Cocaine-related Deficits
NCT01790490
Alprazolam and Eating Behavior in Anorexia Nervosa
NCT01411813
Cognitive Benefits of Aerobic Exercise Across the Age Span
NCT01179958
Gabapentin for Abstinence Initiation in Alcohol Dependence
NCT01141049
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
NCT01748955
Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders
NCT01104805
Enhancing Attention in Adults With Compulsive Hoarding
NCT01100268
Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
NCT00956085
Examining Common Substrates of Eating and Alcohol Use Disorders
NCT01172210
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
NCT01760473
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
NCT01172873
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
NCT00742573
Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)
NCT00728923
The Development of an Eating Laboratory for Overweight Adolescents
NCT00764127
Food Exposure Therapy in Anorexia Nervosa
NCT00755820
Imaging the Dopamine Systems in Bulimia Nervosa
NCT01493362
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
NCT00553319
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
NCT00521352
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
NCT00577408
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
NCT00136786
Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder
NCT00338806
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
NCT00456014
Duloxetine for Chronic Depression: a Double-blind Study
NCT00360724
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755
Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
NCT00529217
Effect of Baclofen on Marijuana Withdrawal and Relapse
NCT00373295
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
NCT00316316
Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder
NCT00247195
Effects of Aripiprazole on Cocaine Craving and Self-Administration
NCT00373880
Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder
NCT00320047
Dronabinol Treatment for Marijuana Addiction
NCT00217971
Antipsychotic Discontinuation in Alzheimer's Disease
NCT00417482
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00218543
Effectiveness of High Intensity Inpatient Versus Stepped Intensity Treatment for Anorexia Nervosa
NCT00815815
Women's Treatment for Trauma and Substance Use Disorders - 1
NCT00078156
Improving Retention of Hispanics Receiving Antidepressant Therapy
NCT00057642
Optimizing Electroconvulsive Therapy for Depression
NCT00045916
Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder
NCT00045903
Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
NCT00288574
Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals
NCT00249483
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
NCT00238914
Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression
NCT00487500
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
NCT00061087
Prozac Treatment of Major Depression: Discontinuation Study
NCT00427128
A Laboratory Model for Heroin Abuse Medications - 8
NCT00000273
IV Cocaine Abuse: A Laboratory Model - 1
NCT00000212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 53 |
| Phase 3 | 4 |
| Phase 4 | 13 |
Therapeutic Areas
What the Pipeline for New York State Psychiatric Institute Shows
According to the ClinicalTrials.gov registry, New York State Psychiatric Institute is linked to 117 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 30% of the sponsor's indexed portfolio — and 77 are already marked complete, representing roughly 66% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for New York State Psychiatric Institute reports 17 late-stage studies (Phase 3 and Phase 4 combined) and 62 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for New York State Psychiatric Institute is Depression with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.